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ABSTRACT
Introduction
The new initiative by the Department of Health and Human Services (DHHS) aims to decrease new HIV infections in the
U.S. by 75% within 5 years and 90% within 10 years. Our objective was to evaluate whether the U.S. military provides
a good example of the benefits of such policies.
Materials and methods
We conducted an analysis of a cohort of 1,405 active duty military personnel with HIV enrolled in the Natural History
Study who were diagnosed between 2003 and 2015 at six U.S. military medical centers. The study was approved by
institutional review boards at the Uniformed Services University of the Health Sciences and each of the sites.We evaluated
the impact of Department of Defense (DoD) HIV care policies, including screening, linkage to care, treatment eligibility,
and combined antiretroviral therapy (cART) initiation on achieving viral suppression (VS) within 3 years of diagnosis.
As a secondary outcome, we evaluated the DoD’s achievement of UNAIDS 90-90-90 targets.
Results
Nearly all (99%) were linked to care within 60 days. Among patients diagnosed in 2003–2009, 77.5% (95% confidence
intervals (CI) 73.9–80.6%) became eligible for cART within 3 years of diagnosis, 70.6% (95% CI 66.6–74.1%) overall
initiated cART, and 64.2% (95% CI 60.1–68.0%) overall achieved VS. Among patients diagnosed in 2010–2015, 98.7%
(95%CI 96.7–99.5%) became eligible for cARTwithin 3 years of diagnosis, 98.5% (95%CI 96.4–99.4%) overall initiated
cART, and 89.8% (95% CI 86.0–92.5%) overall achieved VS.
Conclusions
U.S. military HIV policies have been highly successful in achieving VS goals, exceeding the UNAIDS 90-90-90 targets.
In spite of limitations, including generalizability, this example demonstrates the feasibility of the DHHS initiative to
decrease new infections through testing, early treatment, and retention in care.
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INTRODUCTION
With the introduction of combined antiretroviral therapy
(cART), there have been marked reductions in both trans-
mission of human immunodeficiency virus (HIV) and poor
clinical outcomes among individuals with HIV.1,2 However,
even within resource-rich countries, many individuals with
HIV remain unaware of their status because of lack of
universal screening. Since 1985, the U.S. military has been
testing potential recruits for HIV and has implemented
a force-wide active duty HIV screening program, with
testing approximately every 2 years to assure delivery of
appropriate medical care and protect the military’s unique
walking blood bank.3,4 This policy has facilitated early
diagnosis of HIV infection; specialist care linkage within
60 days for newly diagnosed personnel is directed by another
policy.5–7 Together, these policies provide individual-level
and population-based focus to maximize health and reduce
transmission.
In theUnited States, HIV care in civilian populations can be
complicated by differences in health status, healthcare access,
insurance, and delayed presentation to care. Few U.S. popula-
tions offer the opportunity to study the effects of broad testing
and a universal healthcare system, though recent research
evaluating whether patients with HIV within the Kaiser Per-
manente system met outcome measures provides a detailed
examination of a well-defined patient population.8 Healthcare
access is universal for active duty military personnel, and
the baseline health status of military personnel is generally
without chronic medical conditions. Furthermore, because of
biennial screening, the HIV status of all service members
is largely known and new infections are identified relatively
quickly.
Globally, the United Nations Joint Program on HIV/AIDS
(UNAIDS) has promoted the 90-90-90 approach to end the
AIDS epidemic, which aims to diagnose 90% of all infected
individuals and notify them of their status, initiate cART for
90% of those with a known HIV diagnosis and achieve viral
suppression (VS) in 90%of those initiating cARTworldwide.9
Mathematical models suggest that if 73% (ie 90× 90× 90) of
individuals with HIV worldwide have viral load of HIV RNA
< 1,000 copies/mL, the basic reproductive number (R0) will
fall below 1.0 and HIV transmission will gradually be extin-
guished.9 Achieving theUNAIDS target requires public health
policymakers and clinicians to increase efforts of identifying,
tracking, and retaining patients in care and demands patients
adhere to treatment and remain engaged in care.9 Centers
for Disease Control and Prevention recently estimated that
about 80% of new HIV transmissions in the Unites States are
from individuals who are either not linked to care or unaware
of their status, while no transmissions were identified from
virologically suppressed individuals.10 A continued effort to
improving care linkages, treatment initiation, and achieving
VS will prove vital to ending the epidemic.9
However, the analytical approach in evaluating the HIV
cascade of care stages, including identification, treatment
initiation, and VS, may have an impact on the findings. In
fact, analyses of cohorts and their achievement in reaching the
UNAIDS targets often do not account for mortality or attrition
from the cascade of care. The UNAIDS 90-90-90 targets
use a conditional cross-sectional analysis approach.11 While
analyzing subsequent stages conditioned on achievement of
previous stages follows the strategy employed by UNAIDS
models,9 prior research has suggested that cross-sectional
analyses of the cascade of care can lead to misleading infer-
ence.12
While studies on engagement in care have been conducted
on U.S. veteran and military communities13,14 there have been
no detailed studies aimed at quantifying the effectiveness
of military HIV care at achieving the UNAIDS 90-90-
90 targets. In this study, we quantified the percentage
of participants with HIV who were linked to care, were
eligible for and initiated cART, and achieved VS within
3 years from date of diagnosis. Furthermore, to address
the inherent limitations of cross-sectional approaches in
evaluating achievements in meeting UNAIDS 90-90-90
targets, we also implemented a longitudinal approach to the




The study population was all active duty military personnel
with HIV in the U.S. Military HIV Natural History Study
(NHS) diagnosed between 2003 and 2015. As previously
described, NHS is an open-enrollment cohort with patient
evaluation approximately every 6 months.15 All participants
provide written informed consent. The protocol was approved
by the institutional review board at the Uniformed Services
University of the Health Sciences and the six participating
sites (Madigan Army Medical Center, Naval Medical Center
San Diego, Tripler Army Medical Center, San Antonio Mili-
tary Medical Center, Naval Medical Center Portsmouth, and
Walter Reed National Military Medical Center). We censored
participants upon discharge from active duty or last study
visit.
Setting
Department of Defense (DoD) policy mandates annual med-
ical evaluation of active duty personnel with HIV,4,16 and
each command is responsible to ensure its personnel are
compliant with the policy.16 HIV care for personnel fol-
lows Department of Health and Human Services (DHHS) and
other U.S. guidelines.17 Though there are small differences
in service delivery models, the standards of care across all
military branches are similar. Retention in military service is
based on the service member’s health and ability to perform
duties.
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TABLE I. Cascade of Care Stage Definitions
Cascade stage
HIV diagnosis Due to universal, at least biennial HIV testing, the knowledge of HIV status is nearly 100%.
Linkage to care Record of an infectious disease clinic visit within 60 days of the first positive HIV test.
cART eligibility (based on guidelines) Before October 31, 2009: Any CD4 measure < 200 or a history of OI.
October 31, 2009–December 31, 2012: Any CD4 measure < 350 or a diagnosis of OI. (19, 20)
January 1, 2013–August 31, 2015: Any CD4 measure < 500 or a diagnosis of OI. (21, 22)
September 1, 2015 and later: All HIV+ considered cART eligible. (19, 23)
cART initiation Eligible for cART with a record of cART prescribed after eligibility.
Viral suppression cART prescribed and one or more viral load measures < 200 copies/mL.
cART: combined antiretroviral therapy; OI: opportunistic infections
Data Collection
HIV-1 plasma viral load and CD4 counts are measured at
study visits and captured from interim clinical encounters
through extraction from the centralized Military Healthcare
SystemElectronicMedical Record. Additionally, we collected
data from the NHS database and Military Healthcare System
records on demographics, cART history, and clinical out-
comes.18
Statistical Analyses
We considered the following items as sequential stages: HIV
infection, linkage to care, eligibility for cART based onDHHS
guidelines, cART initiation, and VS (Table I). Each partici-
pant’s treatment eligibility was time varying from late 2009
to late 2015, based on a participant’s last-known CD4 or a
history of an opportunistic infection, and determined by the
guidelines at the time.
We analyzed the cascade of care stages by using two
approaches as recommended by the World Health Organiza-
tion.11 First, we performed a cross-sectional cascade analysis
in which all participants with HIV who were diagnosed within
a given era were included in the denominator for each stage.
An advantage of this analysis is high internal consistency.24 In
this approach, we are using a denominator-numerator linkage
and we assumed the quality of the linked data as high because
they are derived from electronicmedical databases formilitary
personnel. Furthermore, no data were self-reported but rather
obtained from NHS visits and medical records, thus limiting
the biases from conditional linkages.24 Treatment guidelines
changed frequently after 2009, affecting the proportion of
participants eligible for treatment; therefore, we stratified the
estimates into 2003–2009 and 2010–2015 eras. Specifically,
we used the last-known cascade stage reached at the end
of each era (ie 2003–2009 and 2010–2015) to calculate the
proportion of personnel reaching that stage, ie we divided the
total number of personnel with HIV who have reached each
stage by the total number of active duty personnel with HIV
who contributed follow-up to the era.
We also conducted a longitudinal cascade analysis using
an approach previously described by Haber and colleagues12
in which we used Kaplan-Meier estimates of the proportion
of personnel who within 3 years of diagnosis reached each
stage (as recommended by the World Health Organization11,
secondary analyses explored outcomes within 1 and 2 years),
censoring due to time end of data collection and loss to
follow-up because of discharge. Kaplan-Meier estimates were
also used to help illustrate potentially misleading inference
obtained from the cross-sectional cascade approach. To be
considered eligible for a stage, we assumed sequential suc-
cess. For example, to be included in the cART-initiation stage,
the individual also needed to be eligible for cART, as per the
treatment initiation guidelines at the time. Because partici-
pants often transitioned through multiple stages on the same
day (eg linked to care, cART eligibility identified, and cART
initiated), theywere included in the denominator of each stage.
This approach has been previously employed12 to maintain the
conditional linkages between cascade stages.
We defined VS as< 200 copies/mL per DHHS standards,19
though this is more rigid than the World Health Organization
definition of < 1,000 copies/mL.11 For the cross-sectional
cascade analysis, the last viral load prior to the end of
each era was used to determine VS. For the longitudinal
cascade analysis, the lowest viral load observed during
follow-up after cART initiation was used to determine
VS.
In an attempt to determine whether the military met
UNAIDS 90-90-90 targets, we used a conditional cross-
sectional approach according to international guidelines.11
However, previous studies have demonstrated that cross-
sectional analyses of the cascade of care can lead to mislead-
ing inference about the location and severity of issues across
the cascade, related both to accumulation of events over time
and to mortality-shrinking denominators in the cascade.12
To address this, we implemented a longitudinal approach
to the cascade based on the rate at which people transition
through stages. This approach utilizes Kaplan-Meier estimates
of time to transitions between stages, censoring at the point of
discharge and/or end of data collection.
We report Kaplan-Meier estimates with 95% CI. If we
report medians, we also report the respective interquartile
range (IQR). We performed all analyses in R.25 Longitudinal
cascades were generated and estimated using the package
longitudinalcascade.26
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TABLE II. Demographics of U.S. Military HIV Natural History












Officer/warrant officer 151 (10.7)
Missing/unknown 8 (<1.0)









2003–2009 (n = 860)
Median timea (IQR) to first
ID visit, days
21 (12–38)
Median timea (IQR) to cART
initiation (eligibles), days
3 (0–198)
Median timea (IQR) to VS
(those initiating cART), days
81 (28–168)
2010–2015 (n = 545)
Median timea (IQR) to first
ID visit, days
16 (9–28)
Median timea (IQR) to cART
initiation (eligibles), days
0 (0–30)
Median timea (IQR) to VS
(those initiating cART), days
61 (6–145)
cART: combined antiretroviral therapy; IQR: interquartile range
aTime measured in days from previous stage.
RESULTS
From 2003 to 2015, 1,405 active duty personnel with HIV
were newly diagnosed and enrolled in the NHS. Most par-
ticipants were male (97.0%) and either African-American
(42.8%) or Caucasian (36.4%) (Table II). Nearly 90% were
enlisted (88.7%), and themedian age at diagnosis was 27 years
(IQR: 23–34). Of the participants who were diagnosed from
2003 to 2009 (n = 860), the median time from diagnosis to
first HIV clinic visit was 21 days (IQR = 12–38), median
time to cART initiation from eligibility determination was
3 days (IQR = 0–198), and the median time to VS was
81 days (IQR = 28–168) from treatment initiation. Among
participants diagnosed between 2010 and 2015 (n = 545),
the median time from diagnosis to first HIV clinic visit was
16 days (IQR = 9–28), median time to cART initiation from
eligibility determination was 0 days (IQR = 0–30), and the




Among participants diagnosed from 2003 to 2009, 99%
(850/860) were linked to care, 67% (575/860) met criteria
for cART initiation by the end of 2009, 56% (481/860)
initiated cART by the end of 2009, and 44% (381/860)
achieved VS (Fig. 1, panel a). In contrast, among par-
ticipants diagnosed in 2010–2015, 100% (545/545) were
linked to care, 91% (495/545) met criteria for cART
initiation by the end of 2015, 87% (476/545) initiated
cART by the end of 2015, and 81% (440/545) achieved VS
(Fig. 1, panel a).
Longitudinal Cascade Analysis
All study participants were linked to care within 3 years of
diagnosis. We illustrate the speed at which VS was achieved
from time of diagnosis in Figure 1, panel b and Table III.
The participants diagnosed between 2010 and 2015 had better
outcomes than the participants diagnosed between 2003 and
2009. We estimated 77.5% (95% CI: 73.9, 80.6%) of those
diagnosed from 2003 to 2009 became eligible for cARTwithin
3 years of diagnosis, while 98.7% (95% CI: 96.7, 99.5%) of
those diagnosed from 2010 to 2015 became eligible for cART
within 3 years of diagnosis. About, 70.6% (95% CI: 66.6,
74.1%) of those diagnosed from 2003 to 2009 initiated cART,
and 98.5% (95% CI: 96.4, 99.4%) of those diagnosed from
2010 to 2015 initiated cART within 3 years. Lastly, 64.2%
(95% CI: 60.1, 68.0%) of participants diagnosed from 2003
to 2009 achieved VS within 3 years, while 89.8% overall
(95% CI: 86.0, 92.5%) of those diagnosed from 2010 to 2015
achieved VS within 3 years.
We also evaluated cascade achievement within 1 and
2 years of diagnosis using the Kaplan-Meier estimates
(Table III). Nearly all subjects were linked to care within
1 year. Among participants diagnosed from 2003 to 2009,
60.2% (95% CI: 56.4, 63.7%) became cART eligible within
1 year of diagnosis. However, among participants diagnosed
from 2010 to 2015, 89.2% (95% CI: 86.0, 91.7%) became
cART eligible within 1 year of diagnosis. Among participants
diagnosed from 2003 to 2009, 39.5% (95% CI: 35.7, 43.2%)
initiated cART, while 88.0% (95%CI: 84.6, 90.6%) diagnosed
from 2010 to 2015 initiated cART. Lastly, 30.5% (95%
CI: 26.8, 34.0%) of participants diagnosed from 2003 to
2009 achieved VS within 1 year of HIV diagnosis, though
71.7% (95% CI: 67.3, 75.6%) of participants diagnosed from
2010 to 2015 achieved VS within 1 year of HIV diagnosis.
Within 2 years of diagnosis, 69.7% (95% CI: 65.9, 73.0%)
of participants diagnosed from 2003 to 2009 became eligible
for cART; among participants diagnosed from 2010 to 2015,
95.4% (95% CI: 92.9, 97.1%) became eligible for cART
within 2 years of diagnosis. Among those diagnosed from
2003 to 2009, 58.5% (95% CI: 54.4, 62.2%) initiated cART,
though 94.9% (95% CI: 92.2, 96.6%) of those diagnosed from
2010 to2015 initiated cART. Lastly, 50.2% (95% CI: 46.0,
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FIGURE 1. a. Cross-sectional cascade of HIV care trends over time by year of diagnosis contrasted with longitudinal Kaplan-Meier estimates, U.S. Military
HIV Natural History Study Cohort, 2003–2015(n= 1405). Note:Kaplan-Meier estimates with 95% confidence intervals from the longitudinal cascade analysis
displayed for reference in 2003–2009 and 2010–2015 time periods. b. Longitudinal cascade of HIV Care Trends Since Diagnosis Among U.S. Military HIV
Natural History Study Cohort (n = 1405). Note: The curves represent Kaplan-Meier estimates of time to event from the start time of diagnosis, censoring at
time of discharge and last date of data collection for the cohort. Each color represents the cumulative incidence of reaching a particular cascade stage following
the identification.
TABLE III. Longitudinal Cascade of HIV Care Trends Over Time by Year of Diagnosis (2003–2015), U.S. Military HIV Natural History
Study Cohort (n = 1,405)
% Who reached stage within 3 years of diagnosis (95% CI)
2003–2009a 2010–2015a
Linked to care 100 (NA) 100 (NA)
cART eligible 77.5 (73.9–80.6) 98.7 (96.7–99.5)
cART initiation 70.6 (66.6–74.1) 98.5 (96.4–99.4)
Viral suppression 64.2 (60.1–68.0) 89.8 (86.0–92.5)
% Who reached stage within 1 year of diagnosis (95% CI)
2003–2009a 2010–2015a
Linked to care 100 (99.0–100) 99.8 (98.7–100)
cART eligible 60.2 (56.4–63.7) 89.2 (86.0–91.7)
cART initiation 39.5 (35.7–43.2) 88.0 (84.6–90.6)
Viral suppression 30.5 (26.8–34.0) 71.7 (67.3–75.6)
% Who reached stage within 2 years of diagnosis (95% CI)
2003–2009a 2010–2015a
Linked to care 100 (99.0–100) 100 (98.7–100)
cART eligible 69.7 (65.9–73.0) 95.4 (92.9–97.1)
cART initiation 58.5 (54.4–62.2) 94.9 (92.2–96.6)
Viral suppression 50.2 (46.0–54.0) 84.6 (80.7–87.7)
cART: combined antiretroviral therapy; CI: confidence interval
aKaplan-Meier estimates.
54.0) of participants diagnosed from 2003 to 2009 achieved
VS within 2 years, while 84.6% (95% CI: 80.7, 87.7) of
participants diagnosed from 2010 to 2015 achieved VS within
2 years.
To identify health system gaps over time, we illustrate
the cumulative incidence of transitioning across and between
stages in Supplementary Figure 1. The y-intercept represents
the proportion of skipped and simultaneous transitions across
multiple stages. The rates of transition were faster in the
2010–2015 era. Patients diagnosed in the 2003–2009 era were
usually linked to care within a few weeks (median = 21 days;
IQR: 12–38); patients diagnosed from 2010 to 2015 were
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typically linked to care within approximately 2 weeks
(median = 16 days; IQR: 9–28). For patients diagnosed
from 2003 to 2009, from linkage to eligibility for cART
usually occurred within 1 month (median = 29 days; IQR:
14–386). Similarly, among those diagnosed in the 2010–
2015 era, from linkage to care to eligibility for cART
usually occurred within 1 month (median = 29 days; IQR:
14–65). Additionally, most patients who were eligible for
cART in 2003–2009 usually initiated treatment within a
few days of eligibility (median = 3 days; IQR: 0–198), and
patients who were eligible for cART in the 2010–2015 era
usually initiated cART immediately upon determination of
eligibility (median = 0 days; IQR: 0–30). Lastly, patients
who initiated cART in the 2003–2009 era usually achieved
VS within 3 months (median = 81 days; IQR: 28–168), while
patients who initiated cART between 2010 and 2015 typically
achieved VS within about 2 months (median = 61 days; IQR:
6–145).
UNAIDS 90-90-90 Targets
To determine whether the military met UNAIDS 90-90-90
targets, we focused specifically on the identification, cART
initiation, and VS stages among active duty personnel on
the last day of each era. Using the cross-sectional data and
conditionalities defined byUNAIDS,9 by the end of 2009 56%
of those diagnosed initiated cART (481/860) and of those on
cART by the end of 2009 79% achieved VS (381/481) (Fig. 1,
panel a). In contrast, 87% of those diagnosed with HIV by the
end of 2015 initiated cART (476/545), and a larger proportion
of treated participants in the 2010–2015 era achieved VS by
the end of 2015 (92%; 440/476). Using a different analytical
approach, by including time in the analyses using Kaplan-
Meier estimates, we demonstrate rapid transitions between
stages. Specifically, 98.5% (95% CI: 96.4, 99.4%) of those
diagnosed from 2010–2015 initiated cART and 90.3% (95%
CI: 87.3, 92.5%) of those who initiated cART achieved VS
within 3 years.
DISCUSSION
In this cohort of newly diagnosed active duty military person-
nel with HIV, DoD HIV care policies have resulted in linkage
to care within 60 days for nearly everyone. cARTwas initiated
promptly among a large proportion of eligible participants,
and military practices were updated to reflect guidelines for
earlier cART initiation. Treatment has been highly successful;
the achievement of VS in this cohort has continued to increase
bymultiple measures and, as of 2015, approached or exceeded
the UNAIDS target of 90-90-90.
The strategies for prevention of HIV and treatment
employed to optimize the cascade of care within the DoDmay
prove valuable in civilian populations. Some of these strate-
gies in the DoD include pre-exposure prophylaxis services27
and policy-based linkage to universal, open access to care.
U.S. communities have experienced decreased HIV incidence
has decreased in U.S. communities after implementing treat-
all policies,28,29 a treatment as prevention strategy with strong
evidence established from HPTN 05230 and observational
study data.2 Furthermore, the principle of undetectable (viral
load) = untransmittable (U=U) was recently highlighted
by Fauci and colleagues31 and is the roadmap for the new
initiative by DHHS to decrease new infections by 75% within
5 years and 90% within 10 years.31 This ambitious strategy is
the first of its kind in the Unites States, with coordination from
multiple federal agencies focused on populations of interest at
higher risk for HIV from which most new cases are diagnosed
or on rural areas with higher than expected incidence. To
achieve this objective, four pillars have been established: (1)
diagnosing HIV early in all infected, (2) initiating treatment
rapidly to achieve VS, (3) introducing or expanding pre-
exposure prophylaxis particularly to those who are at high
risk, and (4) identifying and responding to HIV clusters.31
U.S. military HIV care policies reflect these principles and
may provide an archetype of what is possible to accomplish
in achieving these pillars nationwide.
We found that the analytical approach substantially
changed the interpretation and inference made from our
results, highlighting some of the key limitations in the cross-
sectional construction of the UNAIDS 90-90-90 goals. Using
the cross-sectional recommendations for the UNAIDS 90-
90-90 targets, we found that by the end of 2015, 87% of
those diagnosed with HIV initiated cART, and of those on
cART, 92% achieved VS. Using this analysis, we might
conclude that the cohort did not meet those goals and that
there are remaining gaps in healthcare coverage related to
HIV/AIDS. However, that conclusion may largely be an
artifact of analyses of outcomes that fail to consider time, as
demonstrated by the rapid transitions observed in analyses,
which include time. Kaplan-Meier estimates suggest that
among participants diagnosed in 2010–2015, 98.5% initiated
cART and 90.3% of those who initiated cART achieved VS
within 3 years. The high rate of treatment initiation and early
transition may be partly because of the military’s obligation to
remain mission ready as well as the health-seeking behaviors
of an active duty population.
LIMITATIONS
Our study has limitations. First, a participant could have
achieved VS before this was ascertained in the cohort setting.
Thus, all estimated survival functions for the time until VS
gives a conservative upper bound. Though the NHS study
schedule follows the standard military HIV care schedule,
there may be differences in motivation with regard to health-
seeking behaviors between those who choose to enroll in
NHS and those who do not. NHS participants who leave the
military prior to retirement (∼3% per year) are not eligible for
continued care or study visits with the DoD and may differ in
health-related behaviors compared with those who remain.
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CONCLUSION
In this cohort of active duty military personnel newly diag-
nosed with HIV, military care policies have resulted in linkage
to care within 60 days for nearly everyone. cARTwas initiated
promptly for more than 98% of personnel, and the rates of
VS have continued to increase over time, exceeding 90%
among those treated in 2010–2015. Regardless of metric,
U.S. military care has approached or exceeded the UNAIDS
targets. The benefits of focused testing and universal access
to healthcare, as evidenced in the military’s integrated, open-
access healthcare system, provide an example of what might
be achieved at a national level with similar policies (see the
Supplementary Panel for an overview of the study objectives,
findings, and future considerations).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at MILMED online.
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